Skip to main navigation Skip to search Skip to main content

Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

  • EMPEROR-Reduced trial committees and investigators

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)35-45
Number of pages11
JournalThe Lancet Diabetes and Endocrinology
Volume10
Issue number1
DOIs
StatePublished - Jan 2022

ASJC Scopus Subject Areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this